Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

ORYZON receives 'Intention to grant' communication for patent relating to the use of vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

2 years ago
vafidemstat, Oryzon, European patent

Oryzon Genomics announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European patent application EP20712565.9 entitled “Methods o...

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

by Ysios Capital

2 years ago
Aura Biosciences, choroidal melanoma (CM), bel-sar (AU-011)

Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile

Investigational antibody-drug conjugate shows promising efficacy in patients with advanced endometrial or ovarian cancer

by VHIO

2 years ago
Datopotamab deruxtecan (Dato-DXd), endometrial or ovarian cancer, TROP2

The phase 2 multicenter TROPION-PanTumor study was designed to evaluate the efficacy of TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with...

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program

by Theriva™ Biologics

2 years ago
proyecto THERICEL, virus adenoasociados (AAV), VCN-01

The THERICEL project is intended to establish the viability of using proprietary Theriva’s A549 suspension cell platform for the clinical manufacture of adenoviral and AAV therapies. Suspension cell...

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

by Ysios Capital

2 years ago
ENX-104, anhedonia (aMDD), Engrail Therapeutics

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers

ORYZON presents the final data from PORTICO, a global Phase IIb vafidemstat trial in Borderline Personality Disorder (BPD), at the European College of Neuropsycopharmacology (ECNP) congress

by Oryzon Genomics

Oryzon announced that it will present today the final data from its Phase IIb PORTICO trial of vafidemstat in patients with Borderline Personality Disorder (BPD) as an oral presentation at the New Med...

Protein behaviour can be predicted with simple maths

by Centre for Genomic Regulation

2 years ago
mutations on protein

In a study published today in the journal Nature, researchers from the Centre for Genomic Regulation (CRG) and the Wellcome Sanger Institute have discovered that mutations affect protein stability fol...

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

by Ysios Capital

2 years ago
Lorundrostat, Hypertension, Mineralys Therapeutics

Mineralys today announced that it has achieved the enrollment target of 261 subjects in the pivotal Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontroll...

Lecanemab y los inicios de una nueva era en el tratamiento del Alzheimer

by Fundación Pasqual Maragall

2 years ago
lecanemab, Alzheimer, donanemab

En enero de 2023 el fármaco recibió la autorización del organismo regulador americano de alimentos y medicamentos, la Food and Drug Administration (FDA), por la vía de aprobación acelerada y, a p...

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

by Oryzon Genomics

2 years ago
vafidemstat, Borderline Personality Disorder (BPD)

Oryzon Genomics announced today the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in Borderline Personality Disorder (BPD) with the US Food and Drug Adm...

CNIO researchers propose a new treatment for brain metastasis based on immunotherapy

by CNIO - Centro Nacional de Investigaciones Oncológicas

2 years ago
brain metastases, immunotherapy, Astrocytes, silibinina

CNIO researchers have discovered that cancer perverts certain brain cells, the astrocytes, and causes them to produce a protein that works in favour of the tumour. A drug, silibinin, inhibits this pro...

Añadir inmunoterapia aumenta supervivencia en cáncer de vejiga

by VHIO

2 years ago
durvalumab, cáncer de vejiga

Demuestran por primera vez los beneficios de una estrategia basada en añadir el fármaco de inmunoterapia durvalumab a la quimioterapia neoadyuvante que se administra antes de la cirugía para extirp...